Sector Watch: Healthcare - Sep 26 2018
This is an archive page. To See the most recent Healthcare Sectorwatch click here
IBB: $120.61 +0.41 0.34% | XBI: $96.12 -0.78 -0.8% | Updated Sep 26, 2018 04:26 PM
| HEALTHCARE STOCKS - TOP GAINERS | ||||
|---|---|---|---|---|
| ALDX52WH Aldeyra Therapeutics $280.0M |
13.35+3.45 21.1 M 181.1x |
35% | ||
| INCR52WH INC Research Holdings $233.8M |
288.00+39.10 6.9 M 3.5x |
16% | ||
| ELMD Electromed $55.1M |
6.65+0.86 1.0 M 42.7x |
15% | ||
| GNCA Genocea Biosciences $71.0M |
0.82+0.10 2.1 M 5.3x |
14% | ||
| XOMA XOMA $139.1M |
18.95+2.36 290.3 K 3.4x |
14% | ||
| HEALTHCARE STOCKS - TOP LOSERS | ||||
|---|---|---|---|---|
| ACET Aceto $73.6M |
2.39-0.44 1.6 M 8.5x |
-16% | ||
| FWP Forward Pharma A/S $106.6M |
2.26-0.32 35.3 K 1.6x |
-12% | ||
| TRUP Trupanion $1.1B |
32.43-3.66 2.4 M 6.7x |
-10% | ||
| MNTA Momenta Pharmaceuticals $1.9B |
24.30-2.40 500.2 K |
-9% | ||
| CASI CASI Pharmaceuticals $445.9M |
5.15-0.48 450.9 K 1.7x |
-9% | ||
Not for trading - Data delayed up to 20 minutes from last update time.
Excludes companies with market caps below $50M.
Market Caps next to company names. Trading volumes below stock prices.
NNx - unusual volume NN times the 3-month avg. volume
52WL - 52-week Low in this trading session
52WH - 52-week High in this trading session
Healthcare Stocks Related News
Trupanion Provides Statement On Regulatory Allegations [globenewswire.com]Aldeyra Therapeutics Announces Positive Results from Phase 2b Dry Eye Disease Clinical Trial [prnewswire.com]
Electromed, Inc. Announces Fiscal 2018 Fourth Quarter Financial Results | Business Wire [businesswire.com]
Aldeyra Therapeutics, Inc. Announces Proposed Public Offering of Common Stock [prnewswire.com]
Trupanion, Inc. (TRUP) Investigated by Block & Leviton LLP For Violations of Federal Securities Laws [prnewswire.com]
Aldeyra Therapeutics Announces Positive Mesothelioma Investigator-Sponsored Clinical Trial Results Presented at The International Association for The Study of Lung Cancer 19th World Conference on Lung Cancer [prnewswire.com]
Aldeyra Therapeutics Schedules Webcast and Conference Call to Announce Results from Phase 2b Dry Eye Disease Clinical Trial [prnewswire.com]
Rollins Set to Join S&P 500; Inogen to Join S&P MidCap 400; Vanda Pharmaceuticals and Garrett Motion to Join S&P SmallCap 600 [prnewswire.com]
Keratoconjunctivitis Sicca (Dry Eye) Report H2 2018 - Review of 41 Companies & Drug Profiles - ResearchAndMarkets.com | Business Wire [businesswire.com]
Global Uveitis Pipeline Review, H2 2018 - 32 Companies & Drug Pipelines - ResearchAndMarkets.com | Business Wire [businesswire.com]
Genocea to Present at Two October Investor Conferences [globenewswire.com]
XOMA Acquires Royalty Interest Position from Agenus on Seven Assets Being Developed by Merck and Incyte [globenewswire.com]
Agenus Closes $15 Million Partial Royalty Monetization With XOMA [prnewswire.com]
Forward Pharma Reports Financial and Operational Results from the First Six Months of 2018 [globenewswire.com]
Get Your Pet Partners With VCA To Help Healthy Pets Across The U.S. Go From One Good Home To Another [prnewswire.com]
Maveron and Lightspeed Venture Partners Lead $8.6 Million Funding in Illumix to Transform AR Gaming | Business Wire [businesswire.com]
Lawsuit for Investors in NASDAQ: ACET shares against Aceto Corporation announced by Shareholders Foundation [globenewswire.com]
Disclaimer Red Acre Investments is not a registered investment advisor and the views and opinions offered herein do not constitute investment advice. Investors should always conduct their own due diligence before trading. You should assume that Red Acre is trading the securities mentioned in our Red Acre Insights, generally in accordance with the views we express, although our positions may change as news evolves. We do not undertake any obligation to update our views as market conditions evolve.
